Pfizer Partners with Innovent Biologics to Advance 12 Early-Stage Oncology Therapies

Pfizer Inc. has announced a strategic global licensing and collaboration agreement with Innovent Biologics to research and develop twelve early-stage cancer medicines, thereby expanding a joint oncology pipeline.

Under the terms of the agreement, Innovent will receive an upfront payment of $650 million and could earn as much as $9.85 billion in milestone payments for development, regulatory, and commercial achievements. Additionally, Innovent will receive tiered royalties on sales of any approved products.

The partnership encompasses twelve programs: eight early-stage initiatives originating from Innovent and four discovery programs identified by Pfizer. The companies will co-develop and share costs for selected programs as they progress through clinical stages, with Innovent advancing the initial candidates using its proprietary drug discovery platform and clinical expertise.

Upon successful completion of Phase 1, Pfizer will assume responsibility for further global development activities.

The collaboration specifies four joint programs that will be co-developed and co-commercialized in the United States and Europe, with profit sharing, while Innovent retains rights to the Greater China market for these programs. Pfizer will obtain exclusive licenses for the remaining programs outside Greater China and will bear the majority of development expenses for those candidates.

The transaction is anticipated to close in the third quarter of 2026, pending satisfaction of customary regulatory and closing conditions.

Source link